In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock edged lower on Tuesday, extending its 10% decline following disappointing earnings, as Novo Nordisk (NYSE: NVO) announced 14 new lawsuits ...